Estradiol in premenstrual asthma: A double-blind, randomized, placebo-controlled, crossover study

Pharmacotherapy

Volumn 23, Issue 5, 2003, Pages 561-571

  Ensom, Mary H H ^a,b,c   Chong, Gina ^a   Zhou, Danyi ^b   Beaudin, Bev ^b   Shalansky, Stephen ^a,b   Bai, Tony R ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIN 1; EOSINOPHIL PROTEIN X; ESTRADIOL; LEUKOTRIENE E4;

ADULT; AIRWAY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; INFLAMMATION; LUNG FUNCTION; PEAK EXPIRATORY FLOW; PREMENSTRUAL SYNDROME; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; STATISTICAL SIGNIFICANCE; SYMPTOM;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ASTHMA; BIOLOGICAL MARKERS; CREATININE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIN-1; EOSINOPHIL-DERIVED NEUROTOXIN; ESTRADIOL; FEMALE; HUMANS; LEUKOTRIENE E4; MENSTRUAL CYCLE; PROGESTERONE; QUALITY OF LIFE; RIBONUCLEASES;

EID: 0038708456     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.5.561.32201     Document Type: Article

References (57)

1. Frank RT. The hormonal causes of pre-menstrual tension, Arch Neurol Psychiatry 1931;26;1053-7.
2. Rees L. An aetiological study of premenstrual asthma. J Psychosom Res 1963;7:1971-7.
3. Claude F, Allemany VR. Asthme et menstruation. Presse Med 1938;38:755-9.
4. Chiray M, Mollard H, Duret M. Asthme et perturbations des secretions hormonales de l'ovaire. Presse Med 1940;16:201-3.
5. Wulfsohn NL, Politzer WM. Bronchial asthma during menses and pregnancy. S Afr Med J 1964;38:173.
6. Aoyama Y, Toyoizumi K, Fueki R, Itoa A, Kobayashi S. Relation between bronchial asthma and the menstrual cycle. Jpn J Allergy 1965;14:583-9.
7. Hanley SP. Asthma variation with menstruation. Br J Dis Chest 1981;75:306-8.
8. Enright T, Lim DT, Devnani R, Mariano R. Cyclical exacerbations of bronchial asthma. Ann Allergy 1987;58:405-6.
9. Gibbs CJ, Coutts II, Lock R, Finnegan OC, White RJ. Premenstrual exacerbation of asthma. Thorax 1984;39:833-6.
10. 2-receptors. Pharmacotherapy 1997;17:224-34.
11. Ensom MHH, Chong E, Carter D. Premenstrual symptoms in females with premenstrual asthma. Pharmacotherapy. 1999;19:374-82.
12. 2-adrenoceptors by exogenous progesterone in female asthmatics. Chest 1997;111:847-51.
13. Tan KS, McFarlane LC, Lipworth BJ. Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill. Am J Respir Crit Care Med 1997;155:1273-7.
14. 2-Adrenoceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pill. Chest 1998;113:278-82.
15. 2-adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax 1997;52:608-11.
16. Baumann G. Estrogen and the hypothalamic-pituitary-adrenal axis in man: evidence for normal feedback regulation by corticosteroids. J Clin Endocrinol Metab 1983;57:1193-7.
17. Josefsson E, Tarkowski A, Carlsten H. Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immunol 1992;142:67-78.
18. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? Circulation 1995;92:5-8.
19. Aoki T, Kojima T, Ono A, et al. Circulating endothelin-1 levels in patients with bronchial asthma. Ann Allergy 1994;73:365-9.
20. Chalmers GW, Little SA, Patel KR, Thomson NC. Endothelin1 induced bronchoconstriction in asthma. Am J Respir Care Med 1997;156:382-8.
21. Merki-Feld GS, Keller PJ. Decrease in endothelin-1 plasma levels during the menstrual cycle and after ethinylestradiol treatment [letter]. Ann Intern Med 1999;131:394.
22. Carlsen KH. Markers of airway inflammation in preschool wheezers. Monaldi Arch Chest Dis 1997;52:455-60.
23. Koller DY, Halmerbauer G, Frischer T, Roithner B. Assessment of eosinophil granule proteins in various body fluids: is there a relation to clinical variables in childhood asthma? Clin Exp Allergy 1999;29:786-93.
24. Morioka J, Kurosawa M, Inamura H, et al. Development of a novel enzyme-linked immunosorbent assay for blood and urinary eosinophil-derived neurotoxin: a preliminary study in patients with bronchial asthma. Int Arch Allergy Immunol 2000;122:49-57.
25. Kristjansson S, Strannegard IL, Strannegard O, Peterson C, Enander I, Wennergren G. Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment. J Allergy Clin Immunol 1996;97:1179-87.
26. Labbe A, Aublet-Cuvelier B, Jouaville L, et al. Prospective longitudinal study of urinary eosinophil protein X in children with asthma and chronic cough. Pediatr Pulmonol 2001;31:354-62.
27. Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;18:584-8.
28. Diamant Z, Timmers MC, van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95:42-51.
29. Bellia V, Bonanno A, Cibella F, et al. Urinary leukotriene E4 in the assessment of nocturnal asthma. J Allergy Clin Immunol. 1996;97:735-41.
30. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
31. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian asthma consensus report, 1999. Canadian asthma consensus group. Can Med Assoc J 1999;161(suppl 11):S1-61.
32. Ng TP. Validity of symptom and clinical measures of asthma severity for primary outpatient assessment of adult asthma. BrJ Gen Pract 2000 50:7-12.
33. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
34. Anonymous. Metropolitan height and weight tables. Stat Bull Jan-Jun, 1983.
35. Chandler MHH, Clifton GD, Louis BA, Coons SJ, Foster TS, Phillips BA. Home monitoring of theophylline levels: a novel therapeutic approach. Pharmacotherapy 1990;10:294-300.
36. 2-adrenergic receptor responsiveness in young and elderly asthmatics. Pharmacotherapy 1992;12:376-82.
37. Rao R, Frederick JM, Enander I, Gregson RK, Warner JA, Warner JO. Airway function correlates with circulating eosinophil, but not mast cell, markers of inflammation in childhood asthma. Clin Exper Allergy 1996;26:789-93.
38. Kabi Pharmacia. Pharmacia CAP System ECP FEIA product information. Uppsala, Sweden; 1992.
39. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832-8.
40. Cayman Chemical Co. Leukotriene E4 enzyme immunoassay kit product information. Ann Arbor, MI; 1996.
41. Snedecor GW, Cochran WG. Statistical methods, 7th ed. Ames, IA: The Iowa State University Press, 1978.
42. Eliasson O, Scherzer HH, DeGraff AC. Morbidity in asthma in relation to the menstrual cycle. J Allergy Clin Immunol 1986;77:87-93.
43. Levine M, Ensom MHH. Post hoc power analysis: an idea whose time has passed? Pharmacotherapy. 2001;21:405-9.
44. Moline ML. Pharmacologic strategies for managing premenstrual syndrome. Clin Pharm 1993;12:182-96.
45. Dhar V, Pearson Murphy BE. The premenstrual syndrome and its treatment. J Steroid Biochem Molec Biol 1991;39:275-81.
46. Zec RF, Trivedi MA. The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev 2002;12:65-109.
47. Tan KS. Premenstrual asthma: epidemiology, pathogenesis and treatment. Drugs 2001;61:2079-86.
48. Juniper EF, Kline PA, Roberts RS, Hargreave FE, Daniel EE. Airway responsiveness to methacholine during the natural menstrual cycle and effect of oral contraceptives. Am Rev Respir Dis 1987;135:1039-42.
49. Beynon HLC, Garbett ND, Barnes PJ. Severe premenstrual exacerbations of asthma: effect of intramuscular progesterone. Lancet 1988;2:370-2.
50. Ozkaragoz K, Cakin F. The effect of menstruation on immediate skin reactions in patients with respiratory allergy. J Asthma Res 1970;7:171-5.
51. Ensom MHH. Gender-based differences and menstrual cycle-related changes in specific diseases: implications for pharmacotherapy. Pharmacotherapy 2000;20:523-39.
52. Nakasato H, Ohrui T, Sekizawa K, et al. Prevention of severe premenstrual attacks by leukotriene receptor antagonist. J Allergy Clin Immunol 1999;104:585-8.
53. Dean NL. Perimenstrual asthma exacerbations and positioning of leukotriene-modifying agents in asthma management guidelines. Chest 2001;120:2116-17.
54. Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002;165:861-6.
55. Dorhofer DM, Sigmon ST. Physiological and psychological reactivity in women with asthma: the effects of anxiety and menstrual cycle phase. Behav Res Ther 2002;40:3-17.
56. Ensom MHH, Chong G, Beaudin B, Shalansky S, Bai TR. Characterizing asthmatics with and without premenstrual asthma [abstr]. Pharmacotherapy 2001;21:1294.
57. Walsh MJ, Polus BI. A randomized, placebo-controlled clinical trial on the efficacy of chiropractic therapy on premenstrual syndrome. J Manipulative Physiol Ther 1999;22:582-5.